Joe joined MedImmune in 2006 as a principal within MedImmune Ventures to assist in deal sourcing and portfolio management and became a Managing Director in 2007. He comes to MedImmune Ventures from Carrot Capital (CCHV) where he was responsible for deal sourcing and had operational roles within CCHV’s portfolio companies. Previously, Joe completed an internship in internal medicine at both New York–Presbyterian Hospital and Memorial Sloan-Kettering Cancer Center. During medical school, Joe was an independent consultant to Arch Venture Partners. He earned a bachelor’s degree in biochemistry from the University of Pennsylvania, and received both a doctorate in immunology and a medical degree from Cornell University’s Weill Medical College. Joe sits on the board of Synovex, Inc and is an observer on the boards of Ambit Biosciences, Inc, Elusys Therapeutics, Inc, and VLST, Inc.

Dr. Jon Andrus returned to PAHO in 2003 after a 10-year absence from the organization, having worked on the polio eradication campaign in the Americas from 1989 to 1993. He serves the Lead Technical Advisor for immunization at PAHO. As of March 2009, he also serves Professor of Global Health at George Washington University and co-director of its MPH program on global health. A graduate of Stanford University, Andrus received his medical degree in 1979 from the University of California at Davis and practiced family medicine for two years in the National Health Service Corps. In 1985, he went to Africa with the Peace Corps. He later trained at the Centers for Disease Control and Prevention before joining PAHO's Expanded Program on Immunization, where he coordinated polio surveillance. In 1993, he became Southeast Asia regional coordinator for polio eradication for the World Health Organization in New Delhi and later served as chief of vaccines and biologicals for Southeast Asia. Currently, Dr. Andrus is the lead investigator of PAHO’s ProVac Initiative, funded by the Bill and Melinda Gates Foundation to enhance national capacity to make evidence-based decisions for the introduction of new vaccines. Dr. Andrus also holds faculty appointments at University California San Francisco and Johns Hopkins School of Public Health.

Dr. Armen is Chairman and Chief Executive Officer of Antigenics Inc., the biotechnology company he co-founded with Pramod Srivastava in 1994. From mid-2002 through 2004, he was Chairman of the Board of Directors for the biopharmaceutical company Elan Corporation, plc. Dr. Armen also serves on the Board of Protagenic Therapeutics, a biotechnology company focusing on human brain hormones for the treatment of mood disorders. He is the founder and President of the Children of Armenia Fund, a charitable organization established in 2000 that is dedicated to the positive development of the children and youth of Armenia

Mr. Auspitz has worked in pharmaceuticals and life-science for over ten years, both in industry and as a consultant. Most recently before joining Fidelity in 2005, he served as Therapeutic Area Head for Immuno-Inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly-listed company (NASDAQ: CRXX). In this role, Mr. Auspitz oversaw the advancement of seven programs from assay stage into phase II human clinical studies, and was co-inventor on 15 product patents. Mr. Auspitz also served as Director for Corporate Strategy at CombinatoRx, where he was responsible for product in-licensing, new business development, and the build-out and $20M financing of an infectious disease subsidiary. His consulting experience has included work in clinical development, product launch, M&A, and medical marketing. Sample projects include sales force optimization and managed markets strategy for Celebrex, the first-in-class COX-2 inhibitor, and clinical development strategy for gene-therapy, protein, and small molecule products. He holds a B.A. from Harvard University. Mr. Auspitz serves on the Board of Directors of Ligocyte Pharmaceuticals

David M. Backer is Director of Business Development and Marketing for SAFC Pharma, a business unit within Sigma-Aldrich that services the CMO marketplace for development and cGMP custom manufacturing of complex small-molecule APIs and biologic drug products. He was formerly President of Molecular Medicine BioServices, a Carlsbad, CA CMO which focuses on biomanufacturing of viral vaccines and therapeutics. Molecular Medicine BioServices was acquired by Sigma-Aldrich in May 2007 and is now part of SAFC Pharma. Dave received his BS in Cellular and Molecular Biology from the University of Michigan and an MBA specializing in high tech marketing from the University of Chicago. He has previously held various technical, sales, marketing and management positions at Abbott Laboratories, Boehringer Mannheim, and Roche Diagnostics.

Dr. Baker is the inventor of the platform technology, founder of NanoBio and an internationally recognized expert in immunology and biologic nanotechnology. Dr. Baker invented the NanoStat technology at the University of Michigan, where he is the Ruth Dow Doan Professor of Medicine and Head of Allergy and Immunology at the Medical School. He is also the Director of the University of Michigan Nanotechnology Institute, which is focused on the use of nanotechnology in biomedical applications. He is one of three editors of the National Nanotechnology Initiative’s Research Directives, and Chairs the Nanotechnology for Medicine and Biology study section at National Institutes of Health (“NIH”). Dr. Baker is a board-certified internist, allergist and immunologist.

Lewellys F. Barker is currently Senior Medical Advisor with the Aeras Global TB Vaccine Foundation in Rockville, Maryland, USA. His major professional interest is in the prevention, treatment and control of infectious diseases with vaccines, drugs and diagnostic tests. He has worked as a bench and clinical scientist and served as a senior manager with the NIH/NIAID's Division of AIDS and NIH's Division of Biologics Standards, the FDA's Bureau of Biologics, the American Red Cross, and Cary Pharmaceuticals, Inc. His responsibilities have encompassed product development, regulation, medical and public health applications of biologics, pharmaceuticals and diagnostics. He has published extensively on his work in preclinical and clinical research on disease detection, epidemiology, risk assessment, treatment and prevention of infectious diseases. He has served on a number of boards and committees and is a past president of the National Health Council and the International Society of Blood Transfusion. He graduated from Princeton University (BA) and the Johns Hopkins University School of Medicine (MD) and School of Hygiene and Public Health (MPH).

Dr. Becker joined VaxInnate in December 2005 with 15 years of vaccine development and industry experience at Sanofi Pasteur, leaving as a Vice President of Corporate Development. With eight years of business development experience, he has expertise in identifying, assessing, negotiating and managing collaborative product development relationships with large pharmaceuticals, biotechnology companies, academic institutions and government agencies, having secured over 30 technologies and products. Prior to his business responsibilities, Dr. Becker headed the immunology section and a vaccine development project at Sanofi Pasteur. His academic experience included junior facility positions at Loyola University Chicago and University of Illinois Chicago in the field of Immunology. Dr. Becker received his Ph.D. in Microbiology and Immunology from the University of Kansas and his MBA from Columbia University.

Dr. Neil Berinstein is a professor in the Department of Medicine at the University of Toronto and the head of the Cancer Vaccine Program for Sanofi Pasteur. At Sanofi, he is responsible for the global research and development of therapeutic vaccines for cancer. Dr. Berinstein has had a distinguished career in the cancer immunotherapy field. After receiving his medical degree at the University of Manitoba and completing training programs in internal medicine and medical oncology at the University of Toronto, Dr. Berinstein worked as a post-doctoral fellow at Stanford University. He has an extensive publication record of papers and book chapters on cancer biology and immunotherapy. He is particularly interested in integrating cancer vaccine approaches with strategies for immune modualtion..

SETH BERKLEY, President, CEO and founder of the International AIDS Vaccine Initiative, a global not-for-profit organization, operational in 24 countries, working to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. He is a medical doctor specializing in infectious disease epidemiology and international health. Prior to founding IAVI in 1996, Dr. Berkley was the Associate Director of the Health Sciences Division at The Rockefeller Foundation. He has worked for the Center for Infectious Diseases of the U.S. Centers for Disease Control, the Massachusetts Department of Public Health, and for the Carter Center, where he was assigned as an epidemiologist at the Ministry of Health in Uganda. In Africa, Dr. Berkley played a key role in Uganda’s national HIV sero-survey and helped develop its National AIDS Control programs.

Dr. Alan Bernstein is an internationally respected researcher, mentor and scientific leader in the fields of cancer, hematopoiesis and genomics. He received his Ph.D. in Medical Biophysics at the University of Toronto in 1972. Following postdoctoral work at the Imperial Cancer Research Fund Laboratories in London (UK), he joined the Ontario Cancer Institute and University of Toronto in 1974. He has been a Professor of Molecular and Medical Genetics since 1984. In 1985, Dr. Bernstein moved to Mount Sinai Hospital as head of Molecular and Developmental Biology of its Samuel Lunenfeld Research Institute. Three years later he became Associate Director and then Director in 1994, a position he held until June 2002 when he was appointed the inaugural President of the Canadian Institutes of Health Research (CIHR). A productive scientist, Dr. Bernstein is the author or co-author of over 200 research articles. He has made key contributions to our understanding of embryonic development, hematopoiesis, cancer and formation of the cardiovascular system. His work has also been important in advancing techniques for gene therapy and the genetic analysis of mammalian development.

Dr. Birkhead is the chief public health physician in the state Health Department. He oversees the activities of DOH's four public health centers and two public health offices: the AIDS Institute, Center for Community Health, Center for Environmental Health, Wadsworth Laboratories, Office of Public Health Practice and the Health Emergency Preparedness Program. In addition to his work at the Department, he is also an Associate Professor of Epidemiology at the School of Public Health, University at Albany and the founding Director of DOH's Preventive Medicine Residency Program. Dr. Birkhead joined the state Health Department in 1988, and served most recently as Director of the AIDS Institute and Director of the Center for Community Health. He was appointed Deputy Commissioner in 2007. Dr. Birkhead is a graduate of the federal Centers for Disease Control and Prevention's Epidemic Intelligence Service and Preventive Medicine Residency programs, and is board-certified in internal medicine and preventive medicine. He holds a medical degree from Yale University School of Medicine and a master's degree in public health from the John Hopkins University School of Hygiene and Public Health.

Durga Bobba joined Merck in 1996 and has worked in US pharmaceutical marketing, business development and international vaccine marketing. He is currently the head of Alliance Management for the Merck Vaccines and Infectious Diseases division which includes responsibility of 6 vaccine alliances on 4 continents. Two of the six alliances generated nearly $2 billion in revenue in 2007. Durga worked in sales for Parke-Davis from 1991-1994 and has an MBA from Georgetown University and a BBA from George Washington University.

Carla Botting directs the Quality Management and Commercial Affairs unit, which comprises four sets of activities: monitoring and evaluation, quality assurance (excluding clinical quality assurance), manufacturing, and business development. Carla has more than ten years of industry experience in business development and in the development and approval of biologics. Prior to joining MVI, Carla was the director of government business development at Cangene Corporation, where she oversaw program management, business development, and government relations in the United States and other industrialized countries. At Cangene, Carla also served as project director for Vaccinia Immune Globulin, taking it from R&D to Food and Drug Administration (FDA) approval. Over the last seven years Carla has worked on joint biological development programs with such partners as the Centers for Disease Control, NIH, the Department of Defense, and the Biomedical Advanced Research and Development Authority. Carla has served on the Board of Directors of the Alliance for BioSecurity and currently serves as a member of the Board of Regents at the University of Winnipeg in Canada. Carla has an honors degree in commerce from the University of Manitoba and has studied French at the University of Caen in France. She has worked in Russia, Ecuador, and the United Kingdom.

Dr. Rick Bright received his PhD in immunology and virology from Emory University. During his training and tenure at the US Centers for Disease Control and Prevention (US CDC), Influenza Division, his career had been focused on studies of avian and human influenza viruses from multiple perspectives including immunology and vaccine development, viral pathogenesis and molecular correlates of pathogenicity, as well as antiviral drugs and the development novel assays for high throughput surveillance of influenza virus resistance to antiviral drugs. With the re-emergence of avian H5N1 viruses into humans in 2003, Dr. Bright turned his focus to surveillance for resistance to antiviral drugs among circulating seasonal and emerging avian influenza viruses. This work culminated in the important discovery of globally high levels of circulating influenza virus showing signs of resistance to adamantanes and renewed research and development in the field of influenza antiviral research. While at the US CDC, Dr. Bright was also a recipient of the Charles C. Shepard Science Award for Scientific Excellence. Dr. Bright has worked in industry, developing transdermal delivery systems for vaccines as well as holding the position of Vice President for Global Influenza Programs at Novavax, Inc. where he was responsible for overseeing two novel virus-like particle influenza vaccine candidates from early discovery into clinical trials. In 2008, Dr. Bright joined PATH as the Scientific Director of the Influenza Vaccine Project in the Vaccine Development Global Program. In this capacity, he provides technical leadership and guidance to PATH and partners to accelerate the development of innovative vaccine and adjuvant candidates against pandemic and seasonal influenza to ensure protection and access to such vaccines for populations of developing countries. Dr. Bright has authored over 20 peer-reviewed articles, chapters, and reviews on influenza immunology, pathogenesis, molecular genetics, vaccines and antiviral drug development. He has served as an ad hoc reviewer and on the editorial board of scientific journals. Dr. Bright has also presented at numerous national and international scientific conferences, made appearances on radio and television programs to educate others about pandemic influenza, and has participated in and chaired focus groups and conferences on behalf of the World Health Organization focusing on the development of pandemic and seasonal influenza vaccine development.

Nicolai Buhl Andersen joined Bavarian Nordic in November 2007. He comes from Coloplast where he held the position as Senior Vice President, Commercial Excellence. He has more than eight years of international experience in leading positions in the field of sales and marketing from Novo Nordisk. He holds a M.Sc. in Economics and Business Administration from Copenhagen Business School.

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Boards of Pharmasset (NASDAQ: VRUS) and BioImagene, and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed (NASDAQ: DEPO), Intranasal, Phytomedics, Proteogenix, Proventys, Targacept (NASDAQ: TRGT) and XDx. Prior to founding Burrill & Company in 1994, he spent 28 years with Ernst & Young, directing and coordinating the firm's services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50). In addition to his work with leading life science companies, Mr. Burrill is a founder and currently serves as the Chairman of the Board of the Foundation for the National Medals of Science and Technology. Additionally, he serves as Chairman of the Board of the Campaign for Medical Research as well as Chairman of the San Francisco Mayor’s Biotech Advisory Committee (MAYBAC). Other not-for-profit activities include serving on the Boards of Directors of the Bay Area Science Infrastructure Consortium, BayBio, California Healthcare Institute (Emeritus), The Exploratorium, The Kellogg Center for Biotechnology, the University of Maryland Biotechnology Institute, the MIT Center for Biomedical Innovation, Kramden Institute, and the National Health Museum. He also serves on the Purdue Discovery Park External Advisory Committee as well as the editorial board of the Journal of Commercial Biotechnology and serves as an advisor to University of Illinois Institute for Genomic Biology, University of Wisconsin—College of Agriculture and Life Sciences, Carnegie Mellon, and Duke University, and is an adjunct professor at University of California, San Francisco.

Dr. Shou-Bai Chao is currently with MedImmune as vice president of Vaccine Manufacturing, responsible for all aspects of global vaccine manufacturing and supply. Dr. Chao will also contribute to MedImmune's commitments to pandemic preparedness. Prior to joining MedImmune, Dr. Chao most recently served as assistant vice president, technical operations and product supply at Wyeth Biotech, where he gained experience bringing FluMist(R) (Influenza Virus Vaccine Live, Intranasal) through development at Wyeth Pharmaceuticals. He was also responsible for global technical operations for the flagship vaccine, Prevnar(R). Prior to Wyeth, Dr. Chao was employed by Sanofi-Pasteur in Quality Assurance, Manufacturing and Technical Services. He brings comprehensive perspective with more than 15 years experience at Wyeth, Sanofi-Pasteur and Philom Bios in global vaccine and bio/pharmaceutical process and product development, manufacturing operations and quality assurance. Dr. Chao earned his doctorate and completed his postdoctoral fellowship at the Industrial Biotechnology Center, University of Waterloo, Ontario, Canada.

Nigel Darby joined GE Healthcare in 2003 and is currently Head of Life Sciences R&D, which develops new products, technologies and services for a wide variety of applications, including biopharmaceutical and vaccine manufacturing, protein science, cell technology, biosensors and drug discovery. This is a 600 strong organization with operations in Sweden, the U.K and the U.S.A From 1997-2003 Darby held a number of positions with AstraZeneca, finally as Vice-President for Chemistry Technology, with responsibility for teams in Sweden, the U.K, Australia and the U.S.A. In this role, he led the development of new approaches to lead discovery and core facilities in compound management, HTS, structural biology, natural product chemistry, computational chemistry and combinatorial chemistry. Prior to entering the pharmaceutical industry Darby had spent 16 years in academic research in medicine and molecular biology with positions at the National Institute for Medical Research in London, the M.R.C Laboratory of Molecular Biology, Cambridge and at the European Molecular Biology Laboratory in Heidelberg, Germany. Darby received his M.A in Natural Sciences from the University of Cambridge in 1981 and his Ph.D in drug metabolism from the University of Kent in 1985.

Matthew M. Davis, MD, MAPP, is Associate Professor of Pediatrics and Communicable Diseases and Internal Medicine at the U-Michigan Medical School and Associate Professor of Public Policy at the Gerald R. Ford School of Public Policy of U-Michigan. His interdisciplinary research centers on the health policy dynamics of the financing and delivery of health care for children and their families. He has collaborated with multiple other investigators across the university and across institutions, and has published over 80 original scientific articles in peer-reviewed journals. His research is funded through a combination of government and foundation sources, including the Centers for Disease Control and Prevention, the Bill & Melinda Gates Foundation, and the Robert Wood Johnson Foundation.

Michelle is the Director of IAVI's Innovation Fund, a grant-giving mechanism targeted primarily at small- and medium-sized biotech companies. Prior to joining IAVI, she served as Manager, Business Development, Marketing and Regulatory Affairs at Innovative Drug Delivery Systems (IDDS), a development stage pharmaceutical company and as an Associate in the venture capital group of Paramount Capital, a boutique biotechnology investment firm. Michelle also served in the Guyana Red Cross Society as a Health Education Coordinator and Director of the Red Cross Children’s Home. Michelle received an Honors Bachelor of Science in Biochemistry and Biotechnology from University of Waterloo (Canada) and completed her Masters of Business Administration (MBA) at the University of Western Ontario.

Mr. Downey is ApoImmune's President and CEO and also serves as Chairman of Board of Directors. Mr. Downey has over 28 years of business experience including 23 years in senior leadership positions with both start-ups and large public corporations. He previously served as the acting CEO and COO of MetaCyte Business Lab LLC, the life sciences business accelerator in Louisville, KY. In 2004, Mr. Downey was named by former Kentucky Governor Ernie Fletcher to the Kentucky Life Sciences Advisory Consortium and was a member of the Board of Directors of the Kentucky Life Sciences Organization. Previously, as Executive Vice President and CFO of Ventas, Inc., a NYSE $200 million revenue real estate investment trust, Mr. Downey actively participated in the restructuring of Vencor, Inc., its primary tenant. At Providian Corporation, he was responsible for the financial operations of the holding company and three divisions with over $20 billion in assets and $2 billion in revenue. He also spent over 12 years with Ernst & Young serving primarily publicly-held clients in the financial services, real estate and health care fields.

Dr. Christopher D. Earl is President and CEO of BIO Ventures for Global Health (BVGH). He previously served as Managing Director of the Perseus-Soros BioPharmaceutical Fund, L.P. (PSBF), a leading investor in later-stage life science companies, where he managed investments in biopharmaceutical companies and served as a director on portfolio company boards. Earlier in his career, Dr. Earl was President and CEO of Avitech Diagnostics, Inc., and a General Partner of Plant Resources Venture Funds. Dr. Earl serves on the board of Asuragen, Inc., and is a Trustee of the Committee for Economic Development. Dr. Earl received a BA in Biology from the University of Pennsylvania, and a PhD in Cellular and Developmental Biology from Harvard University.

Laura Efros is Director, Vaccine Public Policy, in the Vaccine Division of Merck & Co., Inc. She focuses on policies to accelerate access to and enhance funding for vaccines in the U.S. and the developing world. From 2001 to 2002, Dr. Efros was an adviser to the Mailman School of Public Health at Columbia University for the MTCT-Plus program, the first major AIDS treatment program for women and families in sub-Saharan Africa, and to the World Economic Forum's Global Health Initiative. Previously, she served in the Clinton Administration in a joint position as Senior Adviser for International Health with the National Economic Council and Director for International Economic Policy with the National Security Council, where she focused on global AIDS policy. In that capacity, she developed President Clinton's Millennium Vaccine Initiative to accelerate the availability of new vaccines in the lowest-income countries. From 1994 to 1999, she served on the staff of the White House Office of Science and Technology Policy, Division of National Security and International Affairs. She was a Science and Diplomacy Fellow of the American Association for the Advancement of Science from 1993-1995. Dr. Efros received a B.A. in chemistry from Columbia University in 1987 and a Ph.D. in chemistry from Yale University in 1994. She is a member of the Council on Foreign Relations, a Young Leader of the French-American Foundation, and a member of Leadership Philadelphia.

Dr. Egan offers over 30 years of experience with biologics, including 28 years at FDA. At FDA, Dr. Egan served in various director-level positions in the Office of Vaccines Research and Review for more than 10 years, as Chief of the Biophysics Laboratory, as Associate Director for Research for the Office of Vaccines Research and Review (OVRR), as Deputy Director, OVRR, and as Acting Director, OVRR. At OVRR, Dr. Egan had oversight responsibility for vaccine regulation in the United States; he also represented OVRR to various national and international agencies, including the World Health Organization and various National Control Agencies, and to various Congressional bodies. As Associate Director for Research, Dr. Egan was responsible for overseeing the research programs within OVRR. Dr. Egan's research experience within FDA includes 13 years as the Chief for OVRR’s Biophysics Laboratory. There, he brought various physical chemical methods to OVRR for the study of vaccines and other biological macromolecules, primarily the polysaccharide-based vaccines. These methods included NMR spectroscopy, laser light scattering, and computational chemistry. Dr. Egan is an author or co-author of more than 100 scientific articles, primarily in the study of bio-macromolecular structure. Dr. Egan is a member of many professional organizations, including the American Chemical Society and the International Society for Biologicals, where he now serves as Vice-chair of the Human Vaccines Committee; Dr. Egan is also a member of the U.S. Pharmacopoeia’s Vaccines and Virology Expert Working Group. Dr. Egan received his Ph.D. in Chemistry from Princeton University and was a post-doctoral fellow in the Division of Physical Chemistry of the Lund Institute of Technology (Sweden).

Mr. El-Hibri has served as chief executive officer and chairman of the board of directors since June 2004 and as president from March 2006 to April 2007. Mr. El-Hibri served as chief executive officer and chairman of the board of directors of BioPort Corporation from May 1998 until June 2004, when, as a result of our corporate reorganization, BioPort became a wholly owned subsidiary of Emergent. We subsequently renamed BioPort as Emergent BioDefense Operations Lansing Inc. Mr. El-Hibri served as chairman of Digicel Holdings, Ltd., a privately held telecommunications firm, from August 2000 to October 2006. He served as president of Digicel from August 2000 to February 2005. Mr. El-Hibri has served as chairman of East West Resources Corporation, a venture capital and financial consulting firm, since June 1990. He served as president of East West Resources from September 1990 to January 2004. Mr. El-Hibri is a member of the board of trustees of American University and a member of the board of directors of the International Biomedical Research Alliance, an academic joint venture among the NIH, Oxford University and Cambridge University. He also serves as chairman and treasurer of El-Hibri Charitable Foundation. Mr. El-Hibri received a master's degree in public and private management from Yale University and a B.A. in economics from Stanford University.

William “Bill” Enright joined Vaxin in June 2008 and currently serves as President and CEO. Prior to joining Vaxin, Mr. Enright spent six years with GenVec, Inc. with increasing responsibilities including the Head of Business Development. Mr. Enright was responsible for helping to build GenVec’s vaccine business including approximately $140M of funding for vaccine related initiatives and moving four vaccines into clinical development. Mr. Enright brings 20 years of experience in a variety of positions within the life science/biotech industry. Mr. Enright was a self-employed consultant, where he provided business development and strategic marketing services to academic institutions, and a number of small to mid-size life science companies. Prior to becoming a consultant, and after spending several years as a bench scientist at SUNY at Buffalo, Mr. Enright spent 12 years with Life Technologies, Inc. (now Invitrogen), working in various licensing, business management, manufacturing and research roles. Mr. Enright received a Master of Arts in Molecular Biology from SUNY at Buffalo and a Master of Science in Business Management from Johns Hopkins University.

Dr. Fahim is President and Chief Executive Officer of Nabi Biopharmaceuticals. He most recently served as Chief Operating Officer and General Manager. In May 2003, he was named Senior Vice President, Research, Technical and Manufacturing Operations of Nabi Biopharmaceuticals and was Vice President of Vaccine Manufacturing Operations upon joining Nabi Biopharmaceuticals in March 2003. His career includes 14 years with Aventis Pasteur from 1987 to 2001, where he was instrumental in developing several vaccines from early research to marketed products. During his tenure there, he held the positions of Vice President, Industrial Operations; Vice President, Development, Quality Operations and Manufacturing; Director of Product Development; and head of bacterial vaccines research/research scientist. During the year prior to joining Nabi Biopharmaceuticals, Dr. Fahim was an independent consultant, working with Aventis Pasteur and other companies worldwide on projects that included manufacturing, process improvement, quality operations and regulatory issues. From 2001 to 2002, he served as President and Chief Operating Officer of Lorus Therapeutics, Inc., a Toronto-based biopharmaceutical company focused on the research and development of cancer therapies. Dr. Fahim received his Ph.D. in Biochemistry from the University of Toronto.

Sammy Farah joined Versant Ventures in 2007 and specializes in biotechnology investing. He is currently a board observer at Amira Pharmaceuticals, Jazz Pharmaceuticals, Kythera Biopharmaceuticals, Sentient Pharmaceuticals and Trius Therapeutics. Prior to joining Versant, Sammy spent 12 years at Merck & Co., Inc., where he served in several roles. Most recently, Sammy was a Scientific Liaison in the External Scientific Affairs department with primary focus on identifying and evaluating technology acquisition and research opportunities, structuring and negotiating licensing agreements, and building and managing relationships with key external partners for the biologics and oncology franchises. Previously, Sammy worked in the Vaccine Technology and Engineering department at Merck where he managed manufacturing facility start-up, process development and technical support for a number of vaccines including hepatitis A, pneumococcal polysaccharide and haemophilus influenzae type b. Sammy earned his Bachelor of Science in Chemical Engineering from the Massachusetts Institute of Technology, Doctor of Philosophy in Biochemical Engineering from Stanford University and MBA from the Wharton School of Business.

Charles Farkas is partner of Bain & Company. He joined the firm in 1979 and was elected to the partnership in 1985. Mr. Farkas advises chief executives and senior managers in a wide variety of industries on issues critical to long-term success. He has held numerous positions at the firm, currently he is the leader of the North American Healthcare Practice. He has worked globally with companies in pharmaceuticals, medical supplies and devices, pharmaceuticals and biotechnology, diagnostics and laboratory supplies, distribution and hospital and alternate site providers. With over 26 years experience, Mr. Farkas is highly sought out by clients for his experience with issues of growth, strategy, leadership and change. He is the author of the best-selling book Maximum Leadership (1996) and numerous articles in the Harvard Business Review, Fortune, and other publications. Mr. Farkas earned an M.B.A. from Harvard Business School. He is a graduate of Princeton University where he received a Bachelor of Arts in History with honors. From 1976-1978, Mr. Farkas was Fulbright Scholar (ITT International Fellow) in Manila, Philippines. Mr. Farkas serves as a Corporator of Partners Healthcare, is a member of the Board of the Harvard Medical School and is a Governor of the School of The Museum of Fine Arts (Boston).

Tony Ford-Hutchinson obtained his B.Sc. in Biochemistry from the University of Birmingham (1968), a M.Sc. in Molecular Enzymology from the University of Warwick (1969), and a Ph.D. in Biochemistry (1972) from the University of London. Tony joined Merck Frosst Canada in 1981 as Director of Pharmacology coming from Kings College Hospital Medical School, London, UK where he was a lecturer in the Chemical Pathology Department, having carried out research in the field of leukotrienes and prostaglandins. Following several promotions, he was appointed Vice-President of the Merck Frosst Research Laboratories in 1994 and in 1996 also took on additional responsibilities as the principal liaison between Merck Research Laboratories and Banyu Tsukuba Basic Research in Japan. During his 17 years in Canada, the laboratories there have developed novel drugs for the treatment of human bronchial asthma and anti-inflammatory diseases. One major program was to develop a leukotriene receptor antagonist, montelukast (SINGULAIR™), which is now being marketed for the treatment of adult and pediatric asthma and allergic rhinitis. The second major program aimed to produce selective COX-2 inhibitors for the treatment of osteoarthritis and pain. This resulted in the discovery of rofecoxib, and etoricoxib. Tony was appointed Senior Vice President in September 1998 and in 1999 moved to Pennsylvania to head the Basic Research effort at West Point, as well as taking on responsibility for Merck's Research Laboratories in Rome. In 2001 Tony was appointed Executive Vice President with responsibility for all of Worldwide Basic Research within Merck Research Laboratories. In 2005 Merck Research Laboratories moved to a matrix structure and Tony was appointed Executive Vice President, Research Medicine, with responsibilities for strategic direction in Vaccines and Infectious Diseases.

Mark Frohlich, M.D., joined Dendreon in 2005 and was promoted to the position of senior vice president of clinical affairs and chief medical officer in 2007. He previously oversaw medical affairs at Xcyte Therapies. Prior to that was an assistant professor in the Division of Hematology/Oncology at the University of California, San Francisco, where he specialized in urologic oncology and was active in laboratory, translational and clinical research. Dr. Frohlich received his M.D. from Harvard Medical School and did his post doctoral training in oncology at the University of California, San Francisco. He also has a B.S. from Yale in electrical engineering and economics.

Hideki Garren, M.D., Ph.D. co-founded Bayhill in 2001 and currently serves as our Chief Scientific Officer. Since 2003, Dr. Garren has been a member of the adjunct clinical faculty in the Department of Neurology at Stanford University School of Medicine. Dr. Garren received a B.S. from the California Institute of Technology, a Ph.D. in Molecular Biology from the University of California, Los Angeles, Molecular Biology Institute, and an M.D. from the University of California, Los Angeles, School of Medicine.

As Director of the National Vaccine Program Office (NVPO) and the Chair of the Secretary’s Task Force on Influenza Preparedness at HHS, Dr. Bruce Gellin is one of our Nation’s top experts on vaccines and infectious diseases. NVPO was created by Congress to provide leadership and coordination among Federal agencies and other immunization stakeholders, including states and municipalities, health care providers, and private-sector entities such as vaccine manufacturers. Before joining NVPO, Dr. Gellin was the director of the National Network for Immunization Information, an organization he founded to be a resource of up-to-date, authoritative information about vaccines and immunizations. Dr. Gellin has had broad experience in public health aspects of infectious diseases and has held positions at the National Institute of Allergy and Infectious Diseases (NIH), the Centers for Disease Control and Prevention (CDC), the Rockefeller Foundation, and Johns Hopkins University School of Public Health. In addition, he has been a regular consultant to the World Health Organization. He is board certified in internal medicine and infectious diseases and is currently on the faculty at Columbia University School of Public Health, George Washington University School of Medicine, and Vanderbilt University Schools of Medicine and Nursing. Dr. Gellin is a graduate of the University of North Carolina (Morehead Scholar), Cornell University Medical College, and the Columbia University School of Public Health, is an infectious disease expert with training in epidemiology. He has written extensively about public health aspects of infectious diseases in medical and non-medical texts and the peer reviewed medical literature. He is an editor of the Clinical Infectious Diseases Journal’s special section on vaccines and has been a reviewer for over a dozen medical journals. He also served as a medical advisor to Encyclopedia Britannica.

Dr. Gertler is responsible for all investment banking activities related to the biotechnology and specialty pharmaceutical sectors. Dr. Gertler was most recently Managing Director in Healthcare Investment Banking at Cowen and Company. Prior to that, he served as Head of Life Science Investment Banking at Adams Harkness & Hill, focusing on biotechnology and medical technology equity offerings, mergers and acquisitions and strategic advisory projects. He has been responsible for over $5 billion in aggregate deal consideration throughout his banking career. Before joining Adams Harkness in 2001, Dr. Gertler practiced vascular surgery for over twelve years, during which time he published more than 120 peer reviewed manuscripts, abstracts and chapters on vascular surgery and biology. From 1992-2001, Dr. Gertler was one of five vascular surgeons at Massachusetts General Hospital and Associate Professor of Surgery at Harvard University. From 1988-1992, he was Chief of Vascular Surgery at SUNY-HSCB in New York. In addition to his surgical and academic responsibilities, from 1998-2001 Dr. Gertler was a venture partner for Schroder Ventures Life Science Fund, one of the world's largest dedicated life sciences and healthcare private equity funds. He was also co-founder and President of Cardiovascular Technologies, an endovascular device start-up that was successfully sold. Dr. Gertler holds a B.A. from Wesleyan University, an M.D. from Columbia University College of Physicians and Surgeons, and an M.B.A. in Health Policy and Management from Boston University. He trained in general surgery at Yale University and in vascular surgery at Massachusetts General Hospital in Boston.

Douglass Given, MD, PhD, MBA, is an Investment Partner at Bay City Capital and has been with the firm since October 2000. He was formerly: Chief Executive Officer and a director of NeoRx, Corporate Sr. Vice President and Chief Technical Officer of Mallinckrodt, and Chief Executive Officer and a director of Progenitor and Mercator Genetics. He held positions as Vice President at Schering Plough Research Institute, Vice President at Monsanto/G.D. Searle Research Laboratories, and Medical Advisor at Lilly Research Laboratories. Dr. Given is the Chairman of VIA Pharmaceuticals, and Chairman of Vivaldi Biosciences. He is Co-Chairman of the Visiting Committee to the Division of Biological Sciences and the Pritzker School of Medicine at the University of Chicago, a member of the Johns Hopkins Bloomberg School of Public Health Advisory Board, and the Harvard School of Public Health AIDS Initiative International Advisory Council. Dr. Given holds an MD with honors and a PhD from the University of Chicago, and an MBA from the Wharton School, University of Pennsylvania. He was a fellow in Internal Medicine and Infectious Diseases at Harvard Medical School and Massachusetts General Hospital.

Dr. Markus Goebel is a Managing Director of the Novartis Venture Funds in Cambridge, MA, USA. Previously he worked as head Pharma Corporate M&A and head Nervous System BD&L Pharma. An M.D. by training and certified, amongst others, in Haematology/Oncology he worked for Farmitalia Germany and later held several positions in R&D, Marketing and Strategy at Roche headquarters before joining Novartis. Markus Goebel received an M.D. and a Ph.D. from the Ludwig Maximilian’s University in Munich and an MBA from Henley.

Dr. Goodwin has over 15 years experience in management of biomedical development, technology transfer and biomedical product licensing. He has negotiated over 30 licensing deals in the healthcare field. Dr. Goodwin established the technology transfer office at the University of Rochester (NY), which consistently ranks in the top 10 in licensing royalty revenue among university programs in the U.S. He licensed intellectual property covering the HPV VLP vaccine technology to MedImmune that evolved into both GSK’s Cervarix® product and Merck’s Gardasil® product. He also managed an intellectual property portfolio including the Cox-2 gene and the vaccine conjugate technology at the heart of Wyeth’s HibTITER® and Prevnar® products. Dr. Goodwin later directed business development and licensing activities for STS Biopolymers, Inc., a private drug delivery and interventional surgical technology company that was acquired by Angiotech Pharmaceuticals in 2003.

Dr. Gordon has been an innovator in the pharmaceutical industry with over 25 years experience developing both new vaccines and companies. While Director for Bacterial and Viral Vaccines Research at Connaught Laboratories in the US and Canada from 1981 through 1987 he invented and brought to licensure the first bacterial conjugate vaccine, for the prevention of H. influenzae b meningitis. Since that time, he has been President and CEO of three publicly held biotechnology companies. Dr. Gordon is currently serving as a member of the US National Vaccines Advisory Committee and as a member of the Board of Trustees of the Sabin Vaccine Institute.

Dr. Jaap Goudsmit is Crucell’s Chief Scientific Officer and is responsible for all R&D activities. He became a member of Crucell’s Management Board in January 2004. He joined Crucell in 2001 as Senior Vice President Vaccine Research and became a member of Crucell’s Management Committee in July 2002. Prior to that, he held various positions at the Academic Medical Center at the University of Amsterdam and was Chairman of the Research Institute for Infectious Diseases and the Institute for Science Education. Since 1989 he has been a professor at the University of Amsterdam and the Academic Medical Center. He holds a medical degree and a PhD from the University of Amsterdam, the Netherlands.

Mr. Hage is an experienced pharmaceutical marketer who has overseen the marketing of several major drugs over the past 15 years. Mr. Hage oversees business development and marketing strategy. Prior to joining Novavax, Mr. Hage held marketing positions at Eli Lilly & Co. and Cephalon, Inc. Mr. Hage received a B.S. in Business and Economics from the University of Kentucky and an M.B.A. from Ohio State University.

Dr. Hanna is the founder of Vaccinogen, Inc., the discoverer and developer of OncoVAX®, and a pioneer in the field of cancer vaccines. He previously served as Chairman (Emeritus) and Chief Scientific Officer of Intracel Resources, an integrated biopharmaceutical company that developed cancer vaccines and immunotherapeutic and diagnostic products for both cancers and infectious diseases. Dr. Hanna served as President and Chief Executive Officer of PerImmune, Inc. before it and Intracel Corp. merged in 1998. From 1985 to 1994, he was the Chief Operating Officer of Organon Teknika/Biotechnology Research Institute and Senior Vice President of Organon Teknika Corporation, a subsidiary of Akzo Nobel, N.V., The Netherlands. Prior to that, he was Director of the National Cancer Institute, Frederick Cancer Research Center (NCI-FCRC). Dr. Hanna is the discoverer and developer of OncoVAX®. He also developed and obtained FDA approval for TICE BCG for treatment of Carcinoma in Situ ("CIS") bladder cancer. This led to worldwide registration in 1991. It remains the standard of care for prophylaxis of recurrence of superficial bladder cancer and therapy of CIS. In addition to cancer therapy research and development, Dr. Hanna has been intellectually involved in Homeland Security. He served as Chairman of the Department of Commerce Biotechnology Advisory Committee (1984-1989), established to prevent potential biological weapons of mass destruction from being obtained by threat countries and organizations. He also served on the Department of Defense Technical Working Group for Biotechnology (1988-1989). PerImmune, the company that Dr. Hanna founded, completed a Department of Defense contract to manufacture the current effective therapeutic for Botulinum toxin. This product is a therapeutic, equine, heptavalent, despeciated immunoglobulin anti-toxin. Dr. Hanna was Chairman of the Frederick County Local Emergency Planning Committee ("LEPC") responsible for Homeland Security; threat assessment, preparedness and response for a county containing the cross-roads of Baltimore and Washington, D.C., Fort Detrick, FEMA, Camp David, and numerous other sensitive sites. Dr. Hanna received a doctoral degree in experimental pathology and immunology from the University of Tennessee. He has over 250 publications to his credit, has 10 patents in immunotherapy and has been the recipient of numerous honors, and served on many editorial boards.

Deborah joined SR One in 2005, is based in the UK and leads SR One’s activities in Europe. Deborah is a member of the Board of Directors of Addex Pharmaceuticals SA, PharmaKodex and Syntaxin and is an observer on the boards of 7TM and Resistentia Pharmaceuticals AB. Prior to SR One, Deborah was part of GSK's Worldwide Business Development team where she was responsible for sourcing and evaluating in-licensing opportunities in the Psychiatry, Neurology and Gastrointestinal therapeutic areas. During her time with Business Development Deborah led due diligence teams associated with successful in-licensing of preclinical and marketed products as well as a multiple-asset research and development collaboration. Prior to that Deborah held positions of increasing responsibility within SmithKline Beecham's development organisation covering clinical development, medical affairs, medical communications, medical marketing and business development support. She holds a BSc. (Hons.) in Pharmacology from the University of Bath, a PhD in Pharmacology from the University of London, and an MBA from Henley Management College.

Dr. Axel Hoos is Medical Lead in Immunology/Oncology at Bristol-Myers Squibb, holding responsibility for the Ipilimumab (anti CTLA-4) monoclonal antibody program. Dr. Hoos also serves as co-chair of the Executive Committee of the Cancer Vaccine Consortium (CVC) of the New York-based Cancer Research Institute (CRI) and as a member of the Board of Trustees of the Albert B. Sabin Vaccine Institute in Washington D.C. In these capacities he is developing immunotherapies for life-threatening diseases and is spearheading innovative initiatives to foster the dialogue between regulatory, industry and academic stakeholders, and to improve scientific exchange and the drug development process. Previously, Dr. Hoos was Senior Director, Clinical Development at Antigenics Inc., a biotechnology company with focus on developing therapies for cancer and infectious diseases, where he was responsible for strategy and execution of clinical trials in all phases of product development. Dr. Hoos studied medicine at Heidelberg University, Heidelberg, Germany and received his PhD in molecular oncology for work in molecular biology and tumor immunology at the German Cancer Research Center in Heidelberg. He trained in surgery with a focus on surgical oncology at the Technical University in Munich and further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York.

Allan Jarvis is currently Senior Vice President, Corporate Development at Aventis Pasteur, a Division of Aventis Pharmaceuticals. In that capacity he is responsible for the Business Development, Strategic Planning and Process Efficiency and Cost Effectiveness functions. He oversees AvP’s worldwide Corporate Development function and is responsible for managing the company’s growth through alliances, joint-ventures, partnerships, mergers, acquisitions, and the licensing of products and technology. Prior to this, he was Vice President, Business Development and Strategy for the Vaccine Business Unit of Wyeth Pharmaceuticals. Allan received his PhD in Molecular Genetics from the University of California and held NIH Post-Doctoral Fellowships from 1976-1980 at Sloan Kettering Cancer Institute and the Worcester Foundation for Experimental Biology. In 1980, he co-founded Damon Biotech, Inc. where he held diverse positions of increasing responsibility from Manager, Molecular Biology to Vice President, Research and Vice President Business Development. From 1990 to 1992, he worked at Abbott Laboratories, Inc., as Director, Business Development. In 1992 he joined Repligen Corp. in the dual role of Vice President, Business Planning for the parent company and Sr. Vice President, Commercial Development for its wholly owned subsidiary, Amira, Inc. His primary areas of business focus include: strategic planning, valuing products and technology, negotiations and partnership management.

In addition to being appointed Director of the NIAID Division of Extramural Activities, Dr Kalt also serves as the institute’s representative to the NIH extramural program management committee and as an NIAID senior advisor on extramural policy. He comes to NIAID from the Global Health Program of the Bill and Melinda Gates Foundation, where he was responsible for developing the grant-making practices, policies and award mechanisms of the program. Kalt spent 25 years in leadership positions in NIH extramural programs, including service as a senior advisor to the NIH director and as director of NCI’s Division of Extramural Activities. He has received many awards over the course of his government career, including a Presidential Senior Executive Service Meritorious Executive Award and two NIH Director’s awards. Kalt began his NIH career as a scientific review administrator with the National Institute on Aging. He received his Ph.D. in cell and developmental biology from Case Western Reserve University and completed a postdoctoral fellowship at Yale University. He held both NIH and NSF grants while serving as a faculty member in the basic sciences at the University of Connecticut Health Center in Farmington.

Peter H. Khoury, Ph.D., MBA is the Global Vice President for Baxter Vaccines. He obtained his docterate in Microbiology from Syracuse University in 1991, studying the effects of heat shock proteins on the resistance of bacterial spores. Dr. Khoury also holds a MBA from Cornell University's Johnson Graduate School of Management in marketing and general management. Peter has worked during the past fifteen years in various sales and marketing positions of increasing responsibility with Merck Vaccine Division, and Baxter Vaccines. His responsibilities have included Business Development, Promotion Management, Physician and Institutional Sales, Product Management, Database and Direct Marketing, International Marketing, and Global Marketing Strategic Development. He has been a key member of the launch teams for two vaccine products, Varivax and Comvax Dr. Khoury’s current responsibilities in his position as Vice President, Global Marketing for Baxter International (BioScience Division) includes both vaccines sales and marketing for Latin America, North America, Asia, and the Pacific Region, government contracting, and business development.

Kevin P Killeen PhD is Vice-President Research & Business Development at Matrivax Inc., a start-up biotechnology company in Boston, MA. Previously, Dr. Killeen had spent 16 years at AVANT Immunotherapeutics as Senior Director developing live-attenuated bacterial and subunit-based viral vaccines.

Dr. Gerald Kovacs is Director for CBRN Programs in the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. In this position, Dr. Kovacs coordinates Department-wide efforts in the development and acquisition of vaccines, therapeutics, drugs, and diagnostics targeting chemical, biological, radiological, and nuclear threat agents. He is responsible for the development, implementation, and oversight of programs funded by the $5.6 billion authorized by the Project BioShield Act of 2004. Prior to joining BARDA in 2005, Dr. Kovacs was instrumental in establishing the Office of Biodefense Research Affairs at the National Institute of Allergy and Infectious Diseases. He coordinated the research and development of a novel smallpox vaccine for use in the immune-compromised. In 2007, HHS awarded a $500 million contract for 20 million doses of this vaccine to be added to the Strategic National Stockpile. Prior to his career in public service, Dr. Kovacs worked as a research scientist at Wyeth for eight years. During that period, he developed several candidate vaccines for herpes simplex, parainfluenza, and papilloma viruses. He also led the Wyeth’s post-9/11 efforts towards the development of a second-generation smallpox vaccine. Dr. Kovacs graduated from the Department of Biochemistry and Biophysics at Texas A&M University, and subsequently trained as a post-doctoral fellow at Harvard Medical School and the National Institutes of Health.

Dr. Kurilla is the Director of the Office of Biodefense Research Affairs and Associate Director for Biodefense Product Development for the National Institute of Allergy and Infectious Diseases (NIAID). His primary role is to provide overall institute coordination for product development of medical countermeasures against bioterror threats. He received his undergraduate degree in chemistry from the California Institute of Technology. He earned his MD-PhD from Duke University. He took his postgraduate medical training in Pathology at the Brigham & Women’s Hospital in Boston, MA and a postdoctoral fellowship with Dr. Elliott Kieff at Harvard Medical School as a Life Sciences Research Foundation Fellow followed by a Markey Scholar Award. At the University of Virginia, he was an Assistant Professor of Pathology as well as Co-Director of the Laboratory of Molecular Diagnostics and Associate Director for Clinical Microbiology. He moved to the private sector working in anti-infective drug development at Dupont Pharmaceuticals, Bristol-Myers Squibb, and Wyeth. He subsequently joined the National Institute of Allergy and Infectious Diseases (NIAID) as a Medical Officer. In 2005, he was named to his current positions within NIAID.

Reiner Laus was previously Vice President of Research and Development at Dendreon Corporation in Seattle, Washington where he was responsible for discovery, pre-clinical and development functions. He holds a Medical Degree

Staph Bakali is Executive Director at Genocea Biosciences. Over the past 20 years, Mr. Bakali has helped create close to $10 billion in value through senior operating and leadership positions at ID Biomedical [acquired by GlaxoSmithKline], PowderJect Pharmaceuticals [acquired by Chiron], Chiron Vaccines [acquired by Novartis], and board membership at Intercell AG [VSE:ICLL]. Mr. Bakali is the former Chief Operating Officer of ID Biomedical (IDB), a Vancouver, Canada-based company focused on vaccines for influenza. In this role, Mr. Bakali had full responsibility for profit and loss and global operations, including sales and marketing, research and development, industrial operations, quality operations, environmental health and safety. Mr. Bakali managed a staff of more than 500 employees based in five sites located in the U.S. and Canada. Mr. Bakali played a significant role in transforming the company from an R&D organization into a fully-integrated biotech company, and helping IDB double its market cap within two years. He was significantly involved in the acquisition of Shire Biologics by ID Biomedical and led the efforts to integrate the newly acquired company. In 2005, ID Biomedical was acquired by GlaxoSmithKline for $1.4 billion. Prior to ID Biomedical, Mr. Bakali was Chief Operating Officer of Oxford, England-based PowderJect Pharmaceuticals. During his tenure at PowderJect, Mr. Bakali built the commercial and operational organization to over 800 employees in the U.S. and Europe and grew revenue to over $200 million. Mr. Bakali has also been the Director of Worldwide Sales and Marketing at Chiron Vaccines and the Director of SmithKline Beecham plc’s Vaccine Business Unit in France. Mr. Bakali is currently a non-executive Director at Vienna, Austria-based Intercell AG and Director at Canadian mining company Osisko Exploration. Mr. Bakali holds a Masters in Management from London Business School.

Dr Lehmann is Director clinical research and development at Glaxo-SmithKline Biologicals, where he is leading the early clinical development of the Antigen-Specific Cancer Immunotherapeutic (ASCI) program. The aim of this approach is to actively educate the patients’ immune defenses to recognize molecules expressed on the tumor cells and to kill those tumor cells. ASCIs are made of tumor-specific antigens, delivered as recombinant proteins and combined with potent immunological Adjuvant Systems. The ASCI clinical development targets different tumor antigens in numerous of cancer diseases. He completed an internship in internal medicine at the Catholic University of Louvain and a clinical fellowship in medical oncology at the Institute Jules Bordet, Free University of Brussels. His specific area clinical research interest was early clinical development of novel immunologic therapies, with expertise in the treatment of metastatic melanoma. He received postdoctoral training at the Institute Ludwig Institute for Cancer Research. His research focused on T cell tumor immunology and developing cancer vaccines.

Jonathan Liu is Director of Research and Development in AstraZeneca (formerly MedImmune). He is a technical expert with more than 20 years of experience in biological and vaccine R&D and product development. His research spans from early stage research to manufacture process development to GMP clinical trial material production. His technical interest includes developing cell culture based biological and vaccine production processes and identifying and characterizing production cell lines. He also practised veterinary medicine and was a postdoctoral fellow at Harvard Medical School. He has received multiple awards and is a co-inventor of several vaccines and novel biological production processes. His work has been presented at more than 100 scientific conferences and in peer reviewed journals. He has managed many vaccine product development programs successfully including delivery of antibioterrorist stockpiles to US Government and developing cell culture-based pandemic and seasonal influenza vaccines.

Dr. Mansoura is the Acting Deputy Director for Policy, Planning, and Requirements in the Office of the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The mission of the ASPR is to lead the nation in preventing, preparing for, and responding to the adverse health effects of public health emergencies, and natural and manmade disasters. BARDA has a leadership and coordinating role in the research, development, and acquisition of vaccines, therapeutics and diagnostics to address Pandemic Influenza as well as Chemical, Biological, Radiological, and Nuclear (CBRN) threat agents. Dr. Mansoura directs the strategic planning program for the advanced development and acquisition of medical countermeasures and provides policy and strategic leadership for the implementation of the Project BioShield Act of 2004 and the Biomedical Advanced Research and Development Authority (BARDA) under the Pandemic and All-Hazards Preparedness Act. She has led policy and planning efforts that led to the launch of all medical countermeasures acquisition programs under Project BioShield to date with obligations over a billion dollars. She and her team led efforts to develop the HHS Public Health Emergency Medical Countermeasure Enterprise (PHEMCE) Strategy for Chemical, Biological, Radiological and Nuclear Threats and the PHEMCE Implementation Plan for CBRN Threats. The former established guiding principles and a framework for priority-setting and the latter details the top priority targets for medical countermeasure acquisition, including those for purchase with the $5.6 billion dollar Special Reserve Fund under Project BioShield. Dr. Mansoura’s team also develops the program for the annual PHEMCE (formerly BioShield) Stakeholders Workshop. Dr. Mansoura received her Bachelor’s degree in Chemical Engineering from Wayne State University and worked as a reservoir engineer for Shell Western Exploration & Production, Inc., before attending graduate school at the University of Michigan where she earned Master’s Degrees in Bioengineering and Human Genetics, and a Doctoral degree in Bioengineering. Prior to joining BARDA in January 2002 (formerly known as the Office of Research and Development Coordination), she conducted cystic fibrosis research as a Postdoctoral Fellow then worked as a Genomics Program and Policy Analyst at the National Human Genome Research Institute at the National Institutes of Health.

Dean Mason has had the privilege of working in the vaccine profession in 3 major areas: 30 years in government with the Centers for Disease Control and Prevention (CDC), 2 years in the non-profit sector with the Sabin Vaccine Institute (SVI) and currently with Wyeth Vaccines in the private industry sector. At CDC Dean had responsibility for the establishment and management of the Vaccines for Children (VFC) program, a public and private health care partnership that now includes all 50 states and over 80,000 health care providers as participants. He served for two years as President and CEO of the SVI which is dedicated to the supply and utilization of vaccines all over the world. At Wyeth, Dean is the Assistant Vice-President working in vaccine policy. Wyeth's goal is to produce and supply the Pneumococcal Conjugate Vaccine on a global scale.

Margie McGlynn is President of Merck Vaccines & Infectious Diseases. She has responsibility for global leadership of Merck's vaccine and infectious disease businesses. Reporting to the President of Global Human Health, Mr. Ken Frazier, Ms. McGlynn is also a member of Merck's Human Health Leadership Team which has responsibility for preparing, launching, and marketing new products, optimizing the performance of existing products and ensuring a high-performing marketing and sales operation worldwide. Ms. McGlynn was promoted to President, Merck Vaccine Division in August, 2005 from her preceding position as President, U.S. Human Health, to which she was named in January, 2003. Ms. McGlynn joined Merck in 1983. She currently serves on the Board of Directors for Air Products and Chemicals. Margie is also a member of the National Industrial Advisory Committee at the University at Buffalo and from 2006-2008 served on the Board and Executive Committee of the Global Alliance for Vaccine Immunization (GAVI).

Dr. Robert McNally graduated with a Ph.D. in Biomedical Engineering from the University of Pennsylvania and has over 28 years of experience in academic and corporate clinical investigations, management, research, business, quality and regulatory affairs. Dr. McNally is the President and CEO of GeoVax. Previously, he served as President as well as VP of Quality Assurance of Cell Dynamics, a company he co-founded. Cell Dynamics worked with organ and tissue procurement organizations for the recovery of human tissue processing these tissues into cellular components necessary for research and development, pharmaceuticals and cell therapy. In 1984, Dr. McNally co-founded CryoLife, Inc., a company specializing in the cryopreservation of human tissue for transplant. During his 14 year association with CryoLife, it grew to $50M in revenue, became a public company on NYSE and received world recognition as a leader in transplant technology. He is a Fellow of the American Institute of Medical and Biological Engineers, serves on the board of the Petit Institute for Tissue Engineering at Georgia Tech and is Past Chairman of the Georgia Biomedical Partnership and recipient of its 2005 Biomedical Industry Growth Award.

Dr. Midthun is the Deputy Director of Medicine in the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration. CBER regulates vaccines, blood and blood products, and cellular, tissue, and gene therapies. Its responsibilities include oversight of the investigational phases of product development, decisions regarding licensure, and post-licensure surveillance activities. Immediately prior to her current position within FDA, she served as Director of the Office of Vaccines Research and Review within CBER. She has published many articles in peer-reviewed journals, and has represented the FDA at many public meetings and interacted with Congress, both at hearings and briefings. Before joining the FDA in 1993, Dr. Midthun was an assistant professor in the Department of International Health at the Johns Hopkins Bloomberg School of Public Health, where she was involved in the clinical development of several investigational vaccines at the Center for Immunization Research. She also was a faculty member of the Division of Infectious Diseases, Johns Hopkins School of Medicine. Dr. Midthun received her bachelor’s degree from the Massachusetts Institute of Technology and her medical degree from the George Washington University School of Medicine. She trained as a resident in internal medicine at Johns Hopkins Hospital and as a fellow in infectious diseases at Johns Hopkins Hospital and the National Institute of Allergy and Infectious Diseases. She is a fellow of the Infectious Diseases Society of American and a member of the American College of Physicians and the American Society for Virology.

Shankar Musunuri is Senior Director and Strategic Product Leader at Wyeth Biotech in Collegeville, Pennsylvania. He provides manufacturing operations and product supply leadership for some key biotechnology products. He leads cross-functional/multisite product councils (global teams) that are responsible for meeting product objectives and business plan milestones while achieving supply chain excellence throughout the life-cycle of the products. He has been at Wyeth for over 12 years in various roles of increased responsibilities in the areas of strategy, alliance management, manufacturing and supply chain operations, and R&D. Prior to joining Wyeth, Dr. Musunuri worked for Amylin Pharmaceuticals, Inc., San Diego, as a Senior Staff Scientist and the Head of Pharmaceutics. Earlier in his career, Dr. Musunuri worked for McNeil Consumer Products Company in drug delivery research. Dr. Musunuri obtained his MBA (Global Executive) from the Duke University’s Fuqua School of Business and Ph.D. in Pharmaceutics from the University of Connecticut. Dr. Musunuri has authored numerous scientific papers, abstracts, and patents. Dr. Musunuri served as a member of Editorial Advisory Board of the AAPS journal. He served as the Chair (founding) of the San Diego Pharmaceutical Forum, the Chair of AAPS Biotec Section (elected position) in 1999, and Co-Chair of the AAPS National Biotechnology Conference in 2004.

Bartosz Ostenda, Vice President, Healthcare Investment Banking, Goldman, Sachs & Co. BA Magna cum Laude in Biochemical Sciences from Harvard College, 1999; MBA in Finance with Distinction from Kellogg School of Management, 2005. Prior to business school, Bartosz worked first at Global Prior Art in Boston advising biotech and med tech firms on their IP strategy. From 2000 to 2003, he was a consultant at Monitor Group in Cambridge, MA supporting a broad range of clients in defining their corporate, marketing and operational strategies. Since 2004, Bartosz has been working with Goldman, Sachs & Co in their Investment Banking Division - first in London, UK and then in San Francisco, CA advising clients in the biotech and pharma space. Bartosz was involved in a number of vaccine transactions, including sale of Acambis to sanofi pasteur.

Dr. Elliot Parks brings over twenty-five years in biomedical research, product development, executive management, and international venture capital experience to the company. During that time he has had extensive experience in successfully and repeatedly translating important basic research science into commercial products. He was the founding CEO of Myelos Neurosciences a venture-backed, clinical stage biologics company sold to Savient, a NASDAQ listed firm. Prior to Myelos, Dr. Parks was the Director of the Johnson & Johnson Biotechnology Center for ten years, where he was responsible for guiding several biomedical products through clinical trials and regulatory approval. Following receipt of his Ph.D. in Microbiology and Immunology at the University of Washington in Seattle, Dr. Parks assumed research and leadership positions at the Scripps Research Institute during his twelve year tenure there. He also served under the Surgeon General of the Army at Letterman Army Institute of Research in the Presidio in San Francisco.

Andy Pasternak is a partner in Bain’s Healthcare Group, based in Chicago. Prior to joining Bain in 2008, Andy was a partner in the Health & Life Sciences Practice at Oliver Wyman, a global management consultancy. During his 10+ years at Oliver Wyman (formerly named Mercer Management Consulting), Andy served a variety of clients in the pharmaceutical / healthcare sectors, including large pharmaceutical companies, biotechnology firms, private investment funds, NGOs and government agencies. Andy has particular expertise in the biopharmaceuticals arena and has advised clients extensively on issues such as growth strategy, market entry, competitive strategy, M&A, and operational strategy and improvement. Andy is also an internationally recognized strategy consultant in the areas of vaccines and infectious diseases. Andy has authored and spoken extensively on topics relevant to these areas and has served as an advisor to the GAVI Alliance and the World Health Organization. Prior to joining Oliver Wyman, Andy worked in the Corporate Finance Group of J.P. Morgan Securities. Andy earned an M.B.A. from the University of Chicago Graduate School of Business, and a B.A. in Economics from Northwestern University.

Robert is a Co-Founder and Managing General Partner of Lux Capital, focusing on ventures in nanotechnology and life sciences. Robert graduated from the University of Virginia and is a member of the Regional Selection Committee for UVA’s Jefferson Scholars Foundation. Robert is also a member of Motorola's Research Visionary Board and an invited lecturer at the Memorial Sloan-Kettering Cancer Center, the National Cancer Institute, Yale University, University of Washington, and the University of Virginia. He has been published in Journal of Biomedical Materials Research (Applied Biomaterials) and Nature Biotechnology. Robert manages Lux Capital’s investment in Tempo Pharmaceuticals (pharmaceutical nanoencapsulation), Magen Biosciences (dermatology), Molecular Imprints (semiconductor imprint lithography) and Kereos (targeted nanoparticle diagnostics). Robert is a co-founder and Director at Genocea Biosciences (vaccine discovery) and Lux Research (emerging technology research).

Professor Petrovsky graduated in Medicine in 1982 and subsequently trained as a specialist in Endocrinology at the Royal Melbourne Hospital. In 1998, he was awarded a PhD by the University of Melbourne for work on the immunology of type 1 diabetes performed at the Walter and Eliza Hall Institute of Medical Research. He has been a Fellow of the Australian Institute of Company Directors for over 10 years. He is currently the Director, Diabetes and Endocrinology Flinders Medical Centre, South Australia after previously been the Director of the National Health Sciences Centre (NHSC) which conducted clinical trial research and the commercialisation of biomedical research with a particular focus on vaccines. Past management/board experience includes Chairman/Managing Director of Australian Innovation Limited (1996-97), director of Cybergraphic Systems (1995-97) and Chairman of Tasmanian Univalve (1996-97). He is an Adjunct Professor of Flinders University, and has authored over 100 scientific papers and abstracts and holds executive positions with various national and international scientific bodies.

Prior to joining Juvaris, Mr. Pickering founded Pharmada, Inc., where he served as its President and Chief Executive Officer. This biopharmaceutical company focused on the development of small-molecule therapeutics for the treatment of cancer with technology licensed from Fred Hutchinson Cancer Research Center. From 2000 to 2005, Mr. Pickering was employed by Dendreon Corporation in Seattle, Washington and served as a Corporate Officer and most recently as its Senior Vice President of Operations. During his tenure at Dendreon, he led clinical development, manufacturing, sales, marketing, business development, project management and played an important role in fundraising activities, including the company's initial public offering. Prior to Dendreon, he held senior management roles in marketing and business development with Algos Pharmaceutical Corporation culminating in its sale to Endo Pharmaceuticals for $211M. Mr. Pickering was also employed by Johnson & Johnson's Ortho Pharmaceutical Corporation and Glaxo, Inc., where he was highly successful in positions of increasing responsibility in the area of sales and marketing. Mr. Pickering earned his B.S. degree in marketing from the Pennsylvania State University in University Park, PA and his MBA degree with honors from Georgetown University in Washington, DC.

Dr. Gregory Poland is the Director of Mayo Clinic’s Vaccine Research Group – a state-of-the-art research group and laboratory that investigates issues surrounding vaccine response and novel vaccines important to public health. Dr. Poland is a Professor of Medicine and Infectious Diseases and Molecular Pharmacology and Experimental Therapeutics, the Associate Chair for Research for the Department of Medicine, the Director of the Immunization Clinic and the Director of the Program in Translational Immunovirology and Biodefense at Mayo Clinic. He also serves as the President of the International Society for Vaccines and the American Editor for the journal “Vaccine.” In March 2005, Dr. Poland was elected as the President of the Armed Forces Epidemiological Board. He was appointed as the Mary Lowell Leary Professor in Medicine (the highest academic distinction for a faculty member) by Mayo Clinic’s Board of Trustees. In May 2003, he was awarded the Secretary of Defense Medal for Outstanding Public Service. Since 2004, Dr. Poland has also served on the Infectious Diseases Society of America (IDSA) Taskforce on Pandemic Influenza. In 2000, he was appointed as the American Editor for the prestigious medical journal Vaccine. In 1998, he received a joint award from the Centers for Disease Control and Prevention and the Health Care Financing Administration for his contribution to increasing adult immunization rates in the U.S. which was awarded by the Surgeon General of the United States. Also of major significance, in 1997, he was honored as the “Outstanding Clinical Investigator of the Year” by Mayo Clinic. Additionally, Dr. Poland participates on many national and academic review committees and actively peer-reviews journal articles for over 26 different publications such as The Lancet, Annals of Internal Medicine and New England Journal of Medicine. A prolific writer, Dr. Poland has published over 160 peer-reviewed scientific articles and book chapters. Dr. Poland received his medical degree from the Southern Illinois University School of Medicine in Springfield, Illinois, and completed his residency and advanced post-graduate work at the University of Minnesota/Abbott-Northwestern Hospital, Minneapolis, MN.

Dr Hélène Pora is Vaccine Application Development director with Pall LIfe Sciences , where she has the worldwide responsibility for the development of improved separation and purification solutions for the vaccine and gene therapy market. She is also heavily involved in the development of improved single use technologies and related scale-up aspects. Hélène has more than 20 years of experience working for the pharmaceutical and the separation industries, the last 15 years with Pall Corporation. She holds an Engineering Degree in Biochemistry (with Molecular Biology) from the Institut National Agronomique (France) and a PhD in Biochemistry ( on protein engineering and purification) from the University of Orsay (France). Hélène Speaks regularly at conferences about improved separation technologies for the biotechnology and biopharmaceutical industry.

David Rhodes is Head of Business Development for the Health Protection Agency. He is responsible for the external business activities of HPA, including intellectual property management, manufacturing and R&D contracts, and marketing strategy. Originally a plant pathologist, David gained his PhD from the Queen’s University of Belfast before spending a number of years in academic and industrial research at Washington State University and ICI. He was responsible for R&D targeting and North American technology licensing for Zeneca Agrochemicals, and later for various strategic marketing programs in Europe, Africa, Middle East Region for Syngenta. David was awarded the MBA Prize by Henley Management College for his work on valuation of intellectual property, and studied international marketing at INSEAD, France. He is a Certified Licensing Professional and a Fellow of the Royal Society of Medicine.

Dr. Rose was elected Chairman of the Board of SIGA in January 2007. On March 1, 2007, Dr. Rose became the Company’s Chief Executive Officer after taking leave from his position as Chairman of the Department of Surgery and Surgeon-and-Chief of the Columbia Presbyterian Center of New York Presbyterian Hospital, a position he held since August 1994. Dr. Rose has been a member of the Board of Directors of SIGA since April 2001 and served as Interim Chief Executive Officer during April-June 2001. Dr. Rose is a past President of the International Society for Heart and Lung Transplantation. Dr. Rose is also Morris & Rose Millstein Professor of Surgery at Columbia University's College of Physicians and Surgeons` Department of Surgery. Dr. Rose also serves as a Director of Abiomed, Inc., Nephros, Inc. and Keryx Biopharmaceuticals, Inc. Dr. Rose is a graduate of both Columbia College and the Columbia University College of Physicians & Surgeons. In addition to his new roles at SIGA, Dr. Rose has become Executive Vice President – Life Sciences at MacAndrews & Forbes Holdings Inc., a SIGA shareholder.

Dr. Royston is a Founding Managing Partner of Forward Ventures. Dr. Royston has been involved in the biotechnology industry in San Diego from its inception in 1978 with the founding of Hybritech, Inc. (later acquired by Eli Lilly) and with the founding of Idec Pharmaceuticals in 1986 (which later merged with Biogen). Dr. Royston has been instrumental in the formation, financing, and development of numerous successful public biotechnology companies, including: Applied Molecular Evolution (acquired by Eli Lilly); Combichem (acquired by DuPont); Corixa (acquired by GlaxoSmithKline); Favrille; Genesys Therapeutics (merged with Somatix and acquired by Cell Genesys); and Triangle Pharmaceuticals (acquired by Gilead). Currently, Dr. Royston is the founding Chairman of Targegen in San Diego, and was elected Chairman of Morphotek in Exton, PA. He also serves on the Board of Directors of Avalon Pharmaceuticals, and Favrille, where he was the founding Chairman. Dr. Royston was previously the Founding President and CEO of the Sidney Kimmel Cancer Center (1990-2000) and on the faculty of the medical school and cancer center of the University of California, San Diego (1977-1990). He received his B.A. (1967) and M.D. (1970) degrees from the Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. In 1997, President Clinton appointed Dr. Royston to a six-year term on the National Cancer Advisory Board.

Robert’s position is director of External Research and Development (ER&D) in sanofi pasteur the vaccine division of sanofi aventis. The ER&D team is headed by Jeffrey Almond and is positioned at various sites around the globe including the United States, Canada, France, India and China. The ER&D team works closely with our Business Development Group by evaluating the scientific merit of potential external collaborators. Prior to this position, Robert worked in Research where he led the development of their meningococcal conjugate vaccine, now licensed in the United States and Canada under the trade name, Menactra. Robert obtained my PhD in chemistry from the The Pennsylvania State University, and was a post-doctoral fellow at Northwestern University prior to joining sanofi pasteur.

Formerly of AVANT Immunotherapeutics,Inc., T Cell Sciences Inc. and Monsanto Company. Dr Ryan is a seasoned executive having served over 15 years at the helm of a NASDAQ company. She has extensive experience in the biotech industry including serving on the boards of the Biotechnology Industry Association and the Massachusetts Biotechnology Council which she chaired from 2004-2006.

Graziano Seghezzi is a Partner and he invests in life sciences. He started with Sofinnova Partners in April 2006. He started his career in venture capital working for Sofinnova Partners in 2001 and 2002 in Milan for one and a half years, identifying new investment opportunities in pharmaceutical and medical device companies in Italy. Graziano then joined Index Ventures in Geneva where for three years he invested in biotechnology and biopharmaceuticals companies. Currently, Graziano is a board member of Glycovaxyn and Creabilis. After graduating from the University of Pavia in Genetics and Microbiology, he spent five years as a biomedical researcher at New York University's School of Medicine. He also has an MBA from RSM Erasmus University.

Norman C. Selby (Washington, D.C./New York) is a Senior Managing Director at Perseus, L.L.C., a private equity firm with offices in Washington, D.C. and New York. He is responsible for Perseus' strategy and investments in healthcare. Before joining Perseus, Mr. Selby was President and CEO of TransForm Pharmaceuticals, a specialty pharmaceutical company focused on innovation in the form and formulation of drug compounds that was acquired by Johnson & Johnson in April 2005. He was also an Executive Vice President at Citigroup/Citicorp from 1997-2000. Mr. Selby spent the bulk of his career at McKinsey & Company where he was Director (Senior Partner) in the firm's New York office. He held several leadership roles at McKinsey, including head of the firm's Global Pharmaceuticals and Medical Products Practice, head of the New York office's Healthcare and Consumer Industry Practices, and member of the firm's Principals Committee. From 1987-1989, Mr. Selby took a leave of absence from McKinsey to serve as Chief Operating Officer of the New York Blood Center, the largest community blood organization in the country, where he led its financial and operational turnaround. Mr. Selby is a member of the Board of Directors of NanoBio Corporation and Ascenta Therapeutics, Inc. He was on the Board of Millennium Pharmaceuticals (MLNM) from 2000 - 2008. He was also Chairman of Windhover Information, the leading B2B publishing and information company in the pharmaceutical, biotechnology, and medical device industries, from 2004 - 2008, until it was recently sold to Reed Elsevier. Mr. Selby serves on the Board of Trustees of the Central Park Conservancy, the Memorial Sloan-Kettering Cancer Center and the Ralph Lauren Center for Cancer Care and Prevention, all based in New York City. He is also a member of the advisory board of the Harvard Business School's Healthcare Initiative, and a Board member of the National Parks Conservation Association in Washington D.C. Mr. Selby holds a B.A. in Architecture from Yale College and an M.B.A. with Distinction from the Harvard Graduate School of Business Administration.

Dr. John Shiver is Vice President, Worldwide Basic Research Franchise Head, Vaccines, at Merck Research Laboratories in West Point, Pennsylvania, USA. Dr. Shiver is responsible for the worldwide leadership of vaccine basic research for the Infectious Diseases Franchise leading the teams of scientists working to develop novel vaccines against a broad range of diseases, including HIV/AIDS, human papillomavirus, rotavirus, zoster, influenza and bacterial infections. Dr. Shiver has gained international recognition in the scientific community for his leadership of Merck’s novel HIV vaccine research program. He has led Merck’s HIV-1 vaccine research team since 1992 playing an instrumental role in the development of vaccines based on gene delivery technologies and of quantitative immunological assays to measure T cell immune responses. Most recently, he was named as one of the “Top 20 Southerners to Watch” by The Financial Times for his extensive contributions to HIV/AIDS vaccine research. After graduating with a B.S. degree in Chemistry/Mathematics from Wofford College, Dr. Shiver received a Ph.D. in Physical Chemistry from the University of Florida, and completed a postdoctoral fellowship in Biophysics at Purdue University. He joined Merck in 1991 following four years as a Senior Staff Fellow in the Experimental Immunology Branch of the National Cancer Institute, National Institutes of Health. Dr. Shiver is an Editorial Board Member for the Journal of Virology and Drug Discovery Today: Disease Mechanisms. He is a member of the NIH HIV-1 Vaccine Testing Network Laboratory Science Advisory Committee and the Aeras Immunology Technical Advisory Group (a nonprofit group dedicated to the development of tuberculosis vaccines), and the External Steering Committee for the Emory University Vaccine Center. He is a past member of the NIH’s AIDS & Related Research Study Section 2 (1998-2003), Scientific Advisory Board for the Northern California Center for AIDS Research, and expert panel member for the NCRR Regional Primate Research Centers Program Review (1998-99). He has also served on NIH Special Emphasis Panels for “Novel HIV Therapies” (3/00) and “Integrated Preclinical/Clinical AIDS Vaccine Development” (11/97). He has been an invited speaker at numerous scientific conferences including Keystone Symposia (2001, 2003, 2005), the AIDS Vaccine Research Conference International Conference (2001, 2003-5) for which he has also served on the Scientific Program Committee each of these years, Conference for Retroviruses and Opportunistic Infections (2000, 2003), and the International AIDS Conference (2002). In 2006 he was elected as a fellow of the American Academy of Microbiology. Dr. Shiver is the author of more than 100 articles that have been published in leading scientific journals, including Science, Nature, Cell, and the Proceedings of the National Academy of Sciences. In addition, Dr. Shiver is a co-author of 24 awarded patents covering his contributions in the field of novel vaccine development.

Prior to joining ImmunoCellular Therapeutics, Dr. Singh was a Director of California Technology Ventures, an early stage venture capital firm in Pasadena, California, from June 2003 to December 2007. During his tenure at California Technology Ventures, Dr. Singh co-lead investments by that firm in several life sciences companies, including Aliva Biopharmaceuticals, SurgRx, Vivant Medical, Angioscore and Ceregene. He also acted as the interim CEO of Aliva Biopharmaceuticals, a human monoclonal antibody production company focused on creating a greater diversity of antibodies, and was a board member or observer for several companies, including Aliva, Angioscore and Ceregene.

Dr. Singhvi is a recognized vaccine specialist, manufacturing expert and business leader in the pharmaceutical industry. Since assuming his current position, Dr. Singhvi has restructured Novavax to focus on product innovation and development, in particular influenza vaccine development using the company’s novel virus-like particle and Novasome® paucilamellar vesicle technologies. Before joining Novavax, Dr. Singhvi headed vaccine manufacturing operations at Merck & Co., where production increased by 25 percent at the two plants he oversaw. Dr. Singhvi received his M.S. and Sc.D. degrees in Chemical Engineering from the Massachusetts Institute of Technology. He also holds an M.B.A. from the Wharton School.

Dr. Stinchcomb has over 19 years of biotechnology experience including research, product development, approval, and commercialization of vaccines, therapeutics, and diagnostics. His background includes positions as Executive Vice President of Research and Development at Heska Corporation, Director of Biology at Ribozyme Pharmaceuticals (now Sirna acquired by Merck), and Senior Scientist at Synergen (acquired by Amgen). Prior to his career in biotechnology, Dr. Stinchcomb was Assistant and Associate Professor at Harvard University. He obtained his Ph.D. at Stanford University and his B.A. at Harvard University. Currently, he serves as an Adjunct Professor of Biochemistry and Molecular Biology at Colorado State University.

Alan Taggart joined MedImmune as vice president, government project management in September 2006. In this role, he is responsible for coordinating and managing MedImmune’s government projects, including the recently awarded $170 million Health and Human Services cell culture contract. He is also responsible for identifying and capitalizing on additional government contracting opportunities.

Marcel Thalen, aged 43, is currently employed by SynCo Bio Partners as Scientific Officer since 2004, working in Business Development. Before working at SynCo Marcel worked for the Netherlands Vaccine Institute for 14 years in several positions, the last position being head of Process Development. Marcel's main area of expertise is USP, focussing on cell density and/or productivity of a variety of pathogens, in order to replace all substances of animal origin. These developments required an in-depth knowledge and application of the special metabolic requirements of these organisms. Currently at SynCo Marcel is involved in all incoming projects, matching SynCo's capabilities with the clients needs. SynCo offers process development, GMP production as well as fill finish & lyophilization capabilities.

Geert Vanden Bossche was trained in veterinary medicine at the faculty Notre-Dame-de-la-Paix (Namur, Belgium) and the state university of Gent (RUG, Belgium). He received his doctoral degree in veterinary medicine (DVM cum Laude, 1983) from the RUG (Belgium) and earned a senior doctorate (Habilitation, 1996) from the university of Hohenheim (Germany). Following his postdoctoral training in equine medicine and surgery at the Free University of Berlin (Fachtierarzt für Pferde, 1988), he went on to complete additional training in virology, immunology and molecular biology under Hans Ludwig at the Robert Koch institute in Berlin (Germany). He became board certified in virology (Fachtierarzt für Virologie, 1990) and microbiology (Fachtierarzt für Mikrobiologie, 1992). He then transitioned to environmental virology and joined the university of Hohenheim (Germany) as head of the virology research lab. In 1996, he was given the venia legendi in virology and environmental hygiene and held adjunct faculty appointments from the university of Hohenheim (Privatdozent) and the European faculty for environmental sanitation (Gastprofessor) where he has been teaching zoonotic diseases and environmental virology, respectively. During his academic career, Geert has published more than 30 original articles in various scientific fields (including veterinary medicine, immunology, virology and applied colloid science). He also served as a veterinary consultant to the Belgian ministry of agriculture and the ministry of health in 1998 (dioxin crisis), 2000 (BSE and Footh-and-Mouth Disease) and 2002 (nutritional supplements in animal nutrition). In 1995, Geert joined SmithKline Beecham (now GlaxoSmithKline) and worked there for over ten years serving various roles in early and late vaccine development, most recently as head of adjuvant and alternative delivery technologies supporting the development of GSK’s adjuvant portfolio. In this position, he managed an interdisciplinary laboratory adjuvant research program and oversaw the preclinical and extramural work on new adjuvant and vaccine delivery technologies. He pioneered and led efforts to investigate the biophysical behaviour of biologicals and to establish correlates between their biophysical and immunological characteristics. Prior to this role, Geert served as senior project manager on a variety of prophylactic vaccine projects (including streptococcus pneumoniae, genital herpes, improved hepatitis B, ETEC, …). After leaving GSK in 2006, Geert joined Novartis Vaccines & Diagnostics in Siena (Italy) where he served as director on the RSV vaccine project and as head of adjuvants responsible for defining, implementing and managing the company’s adjuvant strategy and due diligence. Before joining the Bill & Melinda Gates Foundation as a senior program officer on the Global Health Discovery team, Geert served as global project director in Solvay Biologicals’ Influenza program devoting his primary efforts to coordinating the preclinical and clinical development of an improved (i.e., adjuvanted) seasonal and pandemic Influenza vaccine.

William L. Warren is CEO and a founder of VaxDesign Corporation. He has been charged with amalgamating business and technical directions along with identifying and bridging the chasms that exist between technology discoveries and business opportunities. Prior to this, he was President of Sciperio Inc., was a program manager at DARPA in the Defense Sciences Office, was a principal member of the technical staff at Sandia National Laboratories, and received his B.Sc. Honors and Ph.D. degrees in Engineering Science from The Pennsylvania State University. Dr. Warren is the author of over 180 referred publications, the editor of three conference proceedings, has over 200 scientific presentations, 7 patents issued, over a dozen pending patents and provisional patents on topics such as in vitro immune models, digital printing systems, microparticle-related immunotherapies, RF communications, water desalination, semiconductor memories and infrared detectors. Dr. Warren has received three R&D 100 awards, the Frost and Sullivan Product Leadership Award, the Industry Week Innovation Award, the Discover Magazine Award, the Xerox Materials Research Award, and several outstanding paper awards. He has organized or co-organized 5 international conferences; is on the board of directors of Sciperio, BioFlorida and a member of the Florida Life Sciences Advisory Committee, and a founding member of bioOrlando.

Mr. Wright joined PharmAthene, Inc. as President and Chief Executive Officer in July 2003. Prior to joining PharmAthene he served as President and Chief Operating Officer of GenVec Inc., and previously President and Chief Business Officer of Guilford Pharmaceuticals. Mr. Wright served as Executive Vice President for MedImmune, Inc. from 1990 to 2000 where he was responsible for building MedImmune's commercial operation and growing product sales from $0 to over $400 million per year. Additionally he has held various marketing and sales positions at pharmaceutical companies including Smith-Kline & French, G.D. Searle and Glaxo. Mr. Wright received his Masters of Arts in Speech Pathology and Audiology from the University of South Florida.

Rinaldo Zurbriggen is the scientific head of Pevion Biotech. He is responsible for the company´s research and development activities including manufacturing- and development processes. Rinaldo Zurbriggen is an initial founder of Pevion Biotech. Prior to joining Pevion Biotech, he was head of the Virus Research Department at Berna Biotech, where he was responsible since 1996 for the development of virosome-based vaccines. During this period his department enabled Berna Biotech to register the first virosome-based vaccine (Epaxal) in Europe. Rinaldo Zurbriggen is a leading expert for virosomes and has published more than 30 papers in peer-reviewed scientific journals in this field. Rinaldo Zurbriggen holds a Master´s degree from the University of Fribourg, Switzerland, and in 1995 obtained his PhD in biochemistry.